Brokerages Set KALA BIO, Inc. (NASDAQ:KALA) PT at $17.25

Key Points

• KALA BIO, Inc. has received a consensus rating of "Buy" from five analysts, with target prices averaging $17.25.
• Insider transactions revealed a director sold 13,227 shares for a total of $53,040, reducing their ownership by 4.87%.
• The company's stock has shown significant growth, with a 400% increase over the past month, reaching a price of $14.55.

KALA BIO, Inc. (NASDAQ:KALA - Get Free Report) has received a consensus rating of "Buy" from the five brokerages that are presently covering the firm, MarketBeat reports. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $21.75.

A number of brokerages have commented on KALA. Wall Street Zen downgraded shares of KALA BIO from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. LADENBURG THALM/SH SH assumed coverage on shares of KALA BIO in a research report on Friday, July 11th. They issued a "buy" rating and a $12.00 target price on the stock. Lifesci Capital raised shares of KALA BIO to a "strong-buy" rating in a research report on Wednesday, September 3rd. HC Wainwright dropped their target price on shares of KALA BIO from $15.00 to $12.00 and set a "buy" rating on the stock in a research report on Friday, May 23rd. Finally, Oppenheimer increased their target price on shares of KALA BIO from $15.00 to $33.00 and gave the company an "outperform" rating in a research report on Thursday.

Insider Activity at KALA BIO

In related news, Director Mark T. Iwicki sold 13,227 shares of the stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $4.01, for a total value of $53,040.27. Following the transaction, the director directly owned 258,433 shares of the company's stock, valued at $1,036,316.33. This trade represents a 4.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last quarter, insiders have sold 30,678 shares of company stock valued at $123,019. Company insiders own 8.32% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. XTX Topco Ltd purchased a new position in shares of KALA BIO in the 2nd quarter valued at $62,000. Readystate Asset Management LP purchased a new position in KALA BIO during the 1st quarter worth $243,000. Geode Capital Management LLC grew its position in KALA BIO by 2.8% during the 2nd quarter. Geode Capital Management LLC now owns 56,367 shares of the company's stock worth $268,000 after purchasing an additional 1,534 shares during the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in KALA BIO by 10.0% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 178,934 shares of the company's stock worth $1,242,000 after purchasing an additional 16,271 shares during the last quarter. Finally, AIGH Capital Management LLC grew its position in KALA BIO by 61.9% during the 1st quarter. AIGH Capital Management LLC now owns 196,350 shares of the company's stock worth $1,125,000 after purchasing an additional 75,048 shares during the last quarter. 24.61% of the stock is owned by hedge funds and other institutional investors.

KALA BIO Stock Up 9.5%

Shares of NASDAQ:KALA traded up $1.62 during trading hours on Monday, reaching $18.62. The stock had a trading volume of 548,207 shares, compared to its average volume of 239,104. KALA BIO has a 1 year low of $2.92 and a 1 year high of $18.89. The firm's 50 day moving average is $8.87 and its 200-day moving average is $6.12. The company has a debt-to-equity ratio of 3.19, a quick ratio of 2.10 and a current ratio of 2.10. The stock has a market capitalization of $130.71 million, a price-to-earnings ratio of -2.74 and a beta of -1.81.

KALA BIO (NASDAQ:KALA - Get Free Report) last announced its quarterly earnings data on Friday, August 8th. The company reported ($1.71) EPS for the quarter, beating analysts' consensus estimates of ($1.82) by $0.11. Research analysts predict that KALA BIO will post -10.84 earnings per share for the current fiscal year.

KALA BIO Company Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.